Encinitas, CA – According to filings with the U.S. Securities and Exchange Commission, Ventyx Biosciences is raising $57,299,993.00 in new funding. Sources indicate as part of senior management Chief Business Officer, Christopher Krueger played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ventyx Biosciences

We are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. Ventyx now includes combined assets from three separate companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting NLRP3 and the inflammasome, and Ventyx Biosciences, targeting TYK2. We selectively modulate key immune targets to create differentiated medicines. Ventyx Biosciences, Inc. is a clinical-stage biotechnology company advancing a broad pipeline of potent and selective small-molecule drug candidates to treat inflammatory diseases and autoimmune disorders.  Ventyx recently completed a $114 million equity financing led by venBio Partners alongside new investors, including Third Point, RTW Investments, LP, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital (a Citadel company), Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA, Cormorant Asset Management, and  participation from founding investor New Science Ventures. Ventyx Biosciences is headquartered in Encinitas, California.

To learn more about Ventyx Biosciences, visit http://ventyxbio.com/

Contact:
Christopher Krueger, Chief Business Officer
858-366-3243
ckrueger@ventyxbio.com
https://www.linkedin.com/in/chris-krueger-46604460/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved